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The findings of this study constitute the first report on the prevalence of Candida species epidemiology in Misrata, Libya. As in
other regions, C. albicans is the most prevalent among all Candida spp. as the cause of oral candidiasis in Libya. Non-albicans




The aim of this study was to explore the prevalence, species distribution and
antifungal sensitivity profile among oral cavity isolates of Candida spp. from
T2DM Libyan patients.
Introduction
Type 2 diabetes mellitus (T2DM), a metabolic disease that is primarily characterized
by abnormal regulation of metabolism, afflicts over 190 million people worldwide
[1,2].
T2DM patients are more vulnerable to fungal infection, particularly Candida
infections of the oral cavity [3-5] due to the increased salivary glucose [6] and the
heightened availability of Candida receptors in these subjects [7].
It has been established that most diabetic patients show at least one lesion or
abnormality in the oral mucosa, such as angular cheilitis, fissured tongue, xerostomia
and erythematous candidiasis [8].
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Figure 3: Distribution of Candida species Isolated from Libyan T2DM patients and
results of disk diffusion assays with fluconazole
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Abstract
Background: There is a paucity of studies describing the prevalence and antimicrobial profiles of Candida in Libya. Limited treatment choices in the antifungal armamentarium in public healthcare settings in Africa 
require a study of the prevalence and susceptibility of Candida species in Libya, where antifungals are not routinely prescribed in public healthcare settings.
Methods: In this study, 170 diabetes mellitus type 2 (T2DM) patients were examined for Candida carriage in the oral mucosa, using differential Fluka and Oxoid chromogenic media and API 32 ID C biochemical testing.
Fluconazole susceptibility was investigated by disk diffusion on YNBG agar. Isolates were graded as susceptible, intermediate or resistant according to their inhibition zone measurements and microcolony scores.
Results: Thirteen species were identified from 182 isolates with a frequency of 68 C. albicans, 42 C. dubliniensis, 26 C. humicola, 20 C. glabrata , 5 isolates of  each C. krusei, C. tropicalis and C. kefyr, 4 C. sake, 2 C. 
parapsilopsis, 2 C. magnoliae and 1 isolate each of C. guilliermondii, C. globosa and  C. membranifaciens. Although largely susceptible to fluconazole, C. albicans, C. dubliniensis, C. humicola and C. sake demonstrated an 
emerging resistance with intermediate to total resistance observed in all the other species except for C. magnolia and C. globosa which were both susceptible to fluconazole.
Conclusion: Early recognition and treatment of rare or resistant Candida species which may be contributing to patient morbidity and mortality in Libya is imperative.
Figure 2: Candida carriage according to gender in the oral mucosa of
T2DM Libyan patients
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 Further attention should be given to fungal infections, by addressing the need to better understand the etiological reasons for
the emergence of rarer species, heightened awareness among medical and public health professionals about these infections
and attention to methods that can be used to prevent and control them.
 Further investigations using molecular microbiology techniques are currently underway in our laboratories to better























5 5 5 4























1 0 1 0 0
No. of Isolates Susceptible Intermediate Resistant
Confirmation of ID using Vitek 2 compact system
Figure 1: Sample collection, characterization and AST steps used in this study
